Jefferies upgrades AstraZeneca to 'buy', hikes price target
(Sharecast News) - Jefferies upgraded its stance on shares of AstraZeneca to 'buy' from 'hold' on Tuesday saying the pharmaceuticals company's impressive revenue and profit trajectory is compelling relative to EU peers, with improving quality of earnings and cash flow generation set to ease concerns.
Read more